Ftse Mib
34.714,00
0,16%
DAX
18.726,76
-0,16%
S&P 500
5.222,68
0,00%
NASDAQ
16.340,87
0,00%
Bitcoin
62.748,87
2,12%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Antares Pharma Inc (ATRS) Antares Pharma Inc (ATRS) Notizie

ATRS

Antares Pharma (ATRS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRS
DataOraFonteTitoloSimboloCompagnia
26/05/202223:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
24/05/202222:50Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ATRSAntares Pharma Inc
24/05/202222:32Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ATRSAntares Pharma Inc
24/05/202222:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
24/05/202215:08Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ATRSAntares Pharma Inc
24/05/202212:11Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ATRSAntares Pharma Inc
13/05/202222:46Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ATRSAntares Pharma Inc
12/05/202214:00PR Newswire (US)Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaNASDAQ:ATRSAntares Pharma Inc
10/05/202223:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATRSAntares Pharma Inc
06/05/202218:10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ATRSAntares Pharma Inc
02/05/202222:50Business WireANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRSNASDAQ:ATRSAntares Pharma Inc
02/05/202212:03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ATRSAntares Pharma Inc
29/04/202223:56Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATRSAntares Pharma Inc
26/04/202213:17Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:ATRSAntares Pharma Inc
26/04/202213:02Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ATRSAntares Pharma Inc
14/04/202212:10Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
13/04/202212:00PR Newswire (US)Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderNASDAQ:ATRSAntares Pharma Inc
29/03/202213:00GlobeNewswire Inc.Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyNASDAQ:ATRSAntares Pharma Inc
07/03/202212:16TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Aclaris Therapeutics (ACRS), Antares Pharma (ATRS)NASDAQ:ATRSAntares Pharma Inc
03/03/202213:00GlobeNewswire Inc.Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsNASDAQ:ATRSAntares Pharma Inc
28/02/202214:30GlobeNewswire Inc.Antares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceNASDAQ:ATRSAntares Pharma Inc
17/02/202214:30GlobeNewswire Inc.Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsNASDAQ:ATRSAntares Pharma Inc
03/02/202214:00GlobeNewswire Inc.Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®NASDAQ:ATRSAntares Pharma Inc
01/02/202223:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRSAntares Pharma Inc
18/01/202213:30GlobeNewswire Inc.Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
12/01/202215:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ATRSAntares Pharma Inc
12/01/202214:30GlobeNewswire Inc.Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesNASDAQ:ATRSAntares Pharma Inc
11/01/202213:30GlobeNewswire Inc.Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
17/12/202113:53GlobeNewswire Inc.MedMira strengthen its Board with New AppointmentNASDAQ:ATRSAntares Pharma Inc
15/12/202123:58GlobeNewswire Inc.Antares Pharma Announces Divestiture of Otrexup®NASDAQ:ATRSAntares Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATRS

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
BFF
BFF Bank
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
ISP
Intesa Sanpaolo
BIT
BPE
Bper Banca
BIT
IVG
Iveco Group NV
BIT
DIA
DiaSorin
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
ENI
Eni
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network